NASDAQ:OPTN OptiNose - OPTN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.71 -0.01 (-0.58%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.68▼$1.7550-Day Range$1.68▼$1.9252-Week Range$1.60▼$4.30Volume95,932 shsAverage Volume145,936 shsMarket Capitalization$142.82 millionP/E RatioN/ADividend YieldN/APrice Target$4.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability OptiNose MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside172.9% Upside$4.67 Price TargetShort InterestBearish3.30% of Shares Sold ShortDividend StrengthN/ASustainability-2.10Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$93,924 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.86) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector450th out of 1,026 stocksPharmaceutical Preparations Industry215th out of 504 stocks 3.5 Analyst's Opinion Consensus RatingOptiNose has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.67, OptiNose has a forecasted upside of 172.9% from its current price of $1.71.Amount of Analyst CoverageOptiNose has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted3.30% of the outstanding shares of OptiNose have been sold short.Short Interest Ratio / Days to CoverOptiNose has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.Change versus previous monthShort interest in OptiNose has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOptiNose does not currently pay a dividend.Dividend GrowthOptiNose does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOptiNose has received a 60.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sumatriptan", "Nasal medication (R01)", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for OptiNose is -2.10. Previous Next 1.8 News and Social Media Coverage News SentimentOptiNose has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.Search Interest3 people have searched for OPTN on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptiNose insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $93,924.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of OptiNose is held by insiders.Percentage Held by Institutions66.26% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptiNose are expected to grow in the coming year, from ($0.86) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptiNose is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptiNose is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About OptiNose (NASDAQ:OPTN) StockOptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.Read More Receive OPTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter. Email Address OPTN Stock News HeadlinesJanuary 31, 2023 | finance.yahoo.comOptinose Announces CEO Transition and Business UpdateDecember 27, 2022 | finance.yahoo.comOptiNose, Inc.'s (NASDAQ:OPTN) top owners are private equity firms with 37% stake, while33% is held by institutionsFebruary 9, 2023 | Vantage Point (Ad)Don’t Let The Markets Break Your HeartEvery rose has its thorn, just like every market has its surprise. If you’re having issues in your trading, it could be that it's not you - it really is the market… Well, you’re in control. You can sit on the sideline when it feels right, or anticipate massive trend reversals with A.I. December 15, 2022 | finance.yahoo.comOptinose Appoints Paul Spence as Chief Commercial OfficerDecember 9, 2022 | finance.yahoo.comOptinose Announces Departure of Acting Chief Financial OfficerNovember 30, 2022 | finance.yahoo.comOptinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare ConferenceNovember 22, 2022 | finance.yahoo.comBucks County health care company expects to raise $50MNovember 21, 2022 | finance.yahoo.comOptinose Announces Pricing of Public Offering of Common Stock and WarrantsFebruary 9, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.November 21, 2022 | finance.yahoo.comOptinose Announces Proposed Public Offering of Common Stock and WarrantsNovember 16, 2022 | finance.yahoo.comAnalysts Are More Bearish On OptiNose, Inc. (NASDAQ:OPTN) Than They Used To BeNovember 12, 2022 | finance.yahoo.comOptiNose Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 10, 2022 | finance.yahoo.comOptiNose (OPTN) Reports Q3 Loss, Misses Revenue EstimatesNovember 9, 2022 | finance.yahoo.comOptinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific MeetingNovember 8, 2022 | finance.yahoo.comOptinose Announces Reporting Date for Third Quarter 2022 Financial ResultsOctober 16, 2022 | finance.yahoo.comShareholders in OptiNose (NASDAQ:OPTN) are in the red if they invested five years ago - Yahoo FinanceOctober 16, 2022 | finance.yahoo.comShareholders in OptiNose (NASDAQ:OPTN) are in the red if they invested five years agoSeptember 30, 2022 | finance.yahoo.comNasal Polyps Treatment Global Market Report 2022 - Yahoo FinanceSeptember 23, 2022 | bizjournals.comSoaring 76 rankings 2022: Greater Philadelphia's fastest-growing companies, Nos. 26-50 - The Business JournalsSeptember 21, 2022 | nasdaq.comA few OptiNose, Inc. (NASDAQ:OPTN) insiders sold shares in the last 12 months: Not a good sign for shareholdersSeptember 19, 2022 | finance.yahoo.comWhen Can We Expect A Profit From OptiNose, Inc. (NASDAQ:OPTN)? - Yahoo FinanceSeptember 18, 2022 | finance.yahoo.comWhen Can We Expect A Profit From OptiNose, Inc. (NASDAQ:OPTN)?September 16, 2022 | reuters.comOPTN.O - OptiNose Inc | Stock Price & Latest News | ReutersSeptember 15, 2022 | globenewswire.comXilio Therapeutics Appoints Tomas J. Heyman to Board of Directors - GlobeNewswireSeptember 12, 2022 | businesswire.comSinusitis Drug Pipeline Insight Report 2022: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, & Impact of Drugs - ResearchAndMarkets.com - Business WireSeptember 7, 2022 | finance.yahoo.comOptinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting - Yahoo FinanceSeptember 6, 2022 | globenewswire.comOptinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting - GlobeNewswireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OPTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter. Email Address OPTN Company Calendar Last Earnings11/10/2022Today2/08/2023Next Earnings (Estimated)3/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPTN CUSIPN/A CIK1494650 Webwww.optinose.com Phone(267) 364-3500FaxN/AEmployees189Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.67 High Stock Price Forecast$5.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+172.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,300,000.00 Net Margins-96.64% Pretax Margin-96.64% Return on EquityN/A Return on Assets-57.05% Debt Debt-to-Equity RatioN/A Current Ratio0.57 Quick Ratio0.51 Sales & Book Value Annual Sales$74.65 million Price / Sales1.91 Cash FlowN/A Price / Cash FlowN/A Book Value($0.26) per share Price / Book-6.58Miscellaneous Outstanding Shares83,520,000Free Float79,511,000Market Cap$142.82 million OptionableNot Optionable Beta-0.25 Key ExecutivesPeter Kaighn MillerChief Executive Officer & DirectorRamy A. MahmoudPresident & Chief Operating OfficerJohn C. MessinaSVP-Clinical Development & Medical AffairsMichael C. BerkeyVice President-Technical OperationsHarry SacksVP-Medical Affairs & Medical OfficerKey CompetitorsAlaunos TherapeuticsNASDAQ:TCRTCue BiopharmaNASDAQ:CUEGracell BiotechnologiesNASDAQ:GRCLVBI VaccinesNASDAQ:VBIVAnnovis BioNYSE:ANVSView All CompetitorsInsiders & InstitutionsRice Hall James & Associates LLCSold 11,304 shares on 1/27/2023Ownership: 0.969%Peter K MillerSold 29,664 sharesTotal: $52,505.28 ($1.77/share)Michael F Marino IIISold 5,241 sharesTotal: $9,276.57 ($1.77/share)Peter K MillerSold 15,253 sharesTotal: $25,777.57 ($1.69/share)Michael F Marino IIISold 2,751 sharesTotal: $4,649.19 ($1.69/share)View All Insider TransactionsView All Institutional Transactions OPTN Stock - Frequently Asked Questions Should I buy or sell OptiNose stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPTN shares. View OPTN analyst ratings or view top-rated stocks. What is OptiNose's stock price forecast for 2023? 2 Wall Street analysts have issued twelve-month target prices for OptiNose's stock. Their OPTN share price forecasts range from $4.00 to $5.00. On average, they predict the company's stock price to reach $4.67 in the next year. This suggests a possible upside of 172.9% from the stock's current price. View analysts price targets for OPTN or view top-rated stocks among Wall Street analysts. How have OPTN shares performed in 2023? OptiNose's stock was trading at $1.85 at the beginning of 2023. Since then, OPTN stock has decreased by 7.6% and is now trading at $1.71. View the best growth stocks for 2023 here. When is OptiNose's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023. View our OPTN earnings forecast. How were OptiNose's earnings last quarter? OptiNose, Inc. (NASDAQ:OPTN) issued its quarterly earnings results on Thursday, November, 10th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The company had revenue of $20.08 million for the quarter, compared to analysts' expectations of $24.20 million. What guidance has OptiNose issued on next quarter's earnings? OptiNose issued an update on its FY 2022 earnings guidance on Tuesday, January, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $74.00 million-$78.00 million, compared to the consensus revenue estimate of $76.07 million. What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX). When did OptiNose IPO? (OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO. What is OptiNose's stock symbol? OptiNose trades on the NASDAQ under the ticker symbol "OPTN." Who are OptiNose's major shareholders? OptiNose's stock is owned by many different institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (0.97%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Joseph C Scodari, Keith A Goldan, Keith A Goldan, Michael F Marino III, Michael F Marino III, Michele Janis, Peter K Miller, Peter K Miller, Ramy A Mahmoud, Ramy A Mahmoud and Victor M Clavelli. View institutional ownership trends. How do I buy shares of OptiNose? Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OptiNose's stock price today? One share of OPTN stock can currently be purchased for approximately $1.71. How much money does OptiNose make? OptiNose (NASDAQ:OPTN) has a market capitalization of $142.82 million and generates $74.65 million in revenue each year. The company earns $-82,300,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. How many employees does OptiNose have? The company employs 189 workers across the globe. How can I contact OptiNose? OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The official website for the company is www.optinose.com. The company can be reached via phone at (267) 364-3500 or via email at investors@optinose.com. This page (NASDAQ:OPTN) was last updated on 2/9/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.